Fevara PLCLSE: FVA

Fevara: Trading Update

· Issued by Fevara PLC

Summary by 6ix AI

Fevara plc, an international specialist in livestock supplements, expects to report revenue from continuing operations of approximately £86 million (FY25: £78.8 million) and adjusted EBIT (earnings before interest and tax) of approximately £6.0 million (FY25: £3.7 million) for the year ended August 31, 2026.

Key details

  • Fevara says expected adjusted EBIT represents c.60% growth and revenue represents 8% like-for-like growth. Company-compiled analyst consensus at September 29, 2026 was revenue of £86.3m and adjusted EBIT of £5.5m.
  • Net debt at year end was c.£2.0 million. Fevara attributes this to trading cash conversion, property disposals and the disposal of Chirton Engineering Ltd (Chirton).
  • Fevara completed a new £20m committed revolving credit facility (a reusable credit line) with HSBC running to November 2028, with two further one-year extension periods available and a further £10m uncommitted facility.
  • Fevara acquired Macal in December 2025, its first entry into Brazil. It also acquired a production facility in São Paulo State, announced in March 2026, where Low Moisture Block production equipment is being installed.
  • In August 2026 Fevara sold Chirton for £0.65 million plus a further £0.2 million deferred over two years, concluding its strategic review.

What’s still pending

  • The FY26 revenue and adjusted EBIT figures are expectations ahead of reported results.
  • Product launch from the São Paulo State facility is scheduled from the fourth quarter of the 2027 financial year.
  • Fevara says it is confident in medium-term targets of £120 million revenue, £15 million adjusted EBITDA, a 10% adjusted EBIT margin and 20% ROCE (return on capital employed).

6ix AI wrote this summary from the release below and checked it against the release.

Fevara PLC
30 September 2026

30 September 2026

Fevara plc

("Fevara", the "Group" or the "Company")

Trading Update

A year of significant milestones and strategic progress; FY26 profitability ahead of market expectations1, with Adjusted EBIT expected to be up c.60% year-on-year

Fevara plc (LSE: FVA), an international specialist in livestock supplements, is pleased to provide a trading update for the year ended 31 August 2026 (“FY26”).

Trading Update

The Group expects to report a strong FY26 performance from continuing operations with revenue expected to be approximately c.£86 million (FY25: £78.8 million), representing 8% like-for-like growth year-on-year, and adjusted EBIT expected to be ahead of market expectations1, at approximately £6.0 million (FY25: £3.7 million), representing c.60% growth year-on-year.

The Group’s UK, European and US businesses all performed well, with sales of Low Moisture Blocks delivering continued growth. Brazil performed as expected in the post-acquisition period.

Financial Position

The Group closed the year with a better than previously anticipated net debt position of c.£2.0 million, due to strong trading cash conversion, alongside the anticipated property disposals and the successful disposal of Chirton Engineering Ltd (“Chirton”).

During the period, Fevara announced the completion of a new £20m Revolving Credit Facility with HSBC. The facility extends to November 2028 with two further, one year extension periods available. In addition to the £20m committed facility the agreement covers the availability of a further £10m uncommitted facility over the same period. This facility has allowed Fevara to complete its acquisitions during FY26, while also providing the headroom for further strategic acquisitions and to support organic growth in line with its growth ambitions.

Strategic progress

The Group delivered against its stated plan to expand into new growth markets through the acquisition of Macal in December 2025, marking Fevara’s first entry into the strategically significant Brazilian market. This was supplemented by the acquisition of a high-specification production facility in São Paulo State announced in March 2026. Installation of the Low Moisture Block production facility in São Paulo State is in progress, with product launch scheduled from Q4 FY27. The Group is particularly encouraged by its long-term growth opportunities in Brazil.

In August 2026, the Group disposed of Chirton for a consideration of £0.65 million with a further £0.2 million deferred over two years. This was the final milestone in the Group’s resolve to simplify operations, right-size the business, and become a pure play international specialist in livestock supplements. This concluded the strategic review to refocus and streamline the organisation.

Outlook

Though early in the new financial year, trading through the first few weeks of FY27 has been encouraging and in line with expectations. As we move into our peak seasonal trading period, largely driven by volumes in our Northern Hemisphere markets, we are pleased with the early progress made.

Our focus remains centred on executing our strategy, improving operating margins, delivering profitable commercial growth and continuing expansion into new markets. The progress we have made to date, and the strategic ambitions that we have in place, leave us confident in our medium-term targets of £120 million revenue, £15 million adjusted EBITDA, an adjusted EBIT Margin of 10% and ROCE of 20%.

Joshua Hoopes, Chief Executive Officer of Fevara plc, commented:

“FY26 has been a year of significant strategic progress, and I am delighted by what we have achieved in the second year of delivering our strategic plan, with the Group expecting to deliver significant growth in adjusted EBIT, ahead of market expectations1.

“Across the business, our teams have worked hard to deliver on all fronts across our strategic pillars as we continue to develop our leading position as an international specialist for livestock supplements. During the year, we have completed a number of significant milestones, including the completion of our strategic refocusing, the delivery of corporate simplification initiatives, further enhancing our portfolio through new product launches and, perhaps most significantly, our entry into the important Brazilian market.

“Against this strong progress, I am confident that Fevara is well positioned to capitalise on the significant growth opportunities ahead.”

1 At 29 September 2026, the Company-compiled analysts’ consensus forecast for the year ended 31 August 2026 is Revenue of £86.3m and Adjusted EBIT of £5.5m.

For further information, please contact:

Enquiries

Fevara plc

Joshua Hoopes, Chief Executive Officer

Gavin Manson, Chief Financial Officer

+44 (0) 1228 554 600

Canaccord Genuity Limited (Corporate Broker)

Max Hartley / Harry Rees

+44 (0)20 7523 8000

Hudson Sandler

Wendy Baker / Nick Moore / Henry Mathieu

+44 (0) 20 7796 4133

About Fevara plc

Fevara is an international specialist in livestock supplements.

Fevara's purpose is to empower farmers in extensive grazing systems with research-proven products that boost profitability, improve resource efficiency and support sustainable agriculture. The Group develops, manufactures and markets research-proven supplements, including feed licks, blocks, bagged minerals, and boluses for cattle, sheep and horses, sold under recognised and trusted brands, including Crystalyx®, Horslic®, Horslyx®, Scotmin Nutrition®, SmartLic®, Tracesure® Advanced and Macal®.

Headquartered in Carlisle, Cumbria, in the UK, Fevara has manufacturing sites in the UK, US and Brazil with operational joint ventures in Germany and the US. It serves customers in more than 20 countries through its expansive international distribution and support network.

Fevara has been listed on the London Stock Exchange since 1972.

For more information, visit: www.fevara.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Fevara PLC on 6ix

Story so far

Earlier from Fevara

Later from Fevara

All Fevara news releases